Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

And The UK's First 'Innovation Passport' Goes To... MSD's Rare Disease Drug Belzutifan

Regulator Invites More Applications For New Pathway

Executive Summary

The MHRA is losing no time in getting its much heralded “new era” of medicines regulation up and running.

You may also be interested in...



Gilead’s Trodelvy To Test UK Innovative Drug Pathway

The cancer drug is also to undergo an accelerated assessment by the European Medicines Agency.

Keeping Track: Recent NDA Submissions Range From Acute Agitation To Von Hippel-Lindau Disease

News and highlights of applications submitted for US FDA approval, from the Pink Sheet’s FDA Performance Tracker

COVID-19 Strengthens Ties Between UK MHRA & NICE On Access To Innovation

New partnerships forged between the UK medicines regulator and health technology assessment bodies during COVID-19 have resulted in an improved understanding of the benefits new drugs can bring to the NHS and how to manage their rapid introduction.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS143860

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel